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HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an effective and immediate
treatment for high-risk acute myeloid leukemia (HR-AML) patients lacking matched donors. Relapse remains
the leading cause of death for HR-AMLpatients after haplo-HSCT. Accordingly, the prevention of relapse remains
a challenge in the treatment of HR-AML. In amulticenter randomized controlled trial in southwestern China,178
HR-AML patients received haplo-HSCT with conditioning regimens involving recombinant human granulocyte
colonyestimulating factor (rhG-CSF) or nonerhG-CSF. The cumulative incidences of relapse and graft-versus-
host disease (GVHD), 2-year leukemia-free survival (LFS), and overall survival (OS) were evaluated. HR-AML
patients who underwent the priming conditioning regimen with rhG-CSF had a lower relapse rate than those
who were treated with non-rhG-CSF (38.2%; 95% conﬁdence interval [CI], 28.1% to 48.3% versus 60.7%, 95% CI,
50.5% to 70.8%; P < .01). The cumulative incidences of acute GVHD, chronic GVHD, transplantation-related
toxicity, and infectious complications appeared to be equivalent. In total, 53 patients in the rhG-CSFepriming
group and 31 patients in the non-rhG-CSFepriming group were still alive at the median follow-up time of
42 months (range, 24 to 80 months). The 2-year probabilities of LFS and OS in the rhG-CSFepriming and non-
rhG-CSFepriming groups were 55.1% (95% CI, 44.7% to 65.4%) versus 32.6% (95% CI, 22.8% to 42.3%) (P< .01) and
59.6% (95% CI, 49.4% to 69.7%) versus 34.8% (95% CI, 24.9% to 44.7%) (P< .01), respectively. Multivariate analyses
indicated that the 2-year probability of LFS of patients who achieved complete remission (CR) before trans-
plantationwas better than that of patientswho did not achieve CR. The 2-year probability of LFS of patientswith
no M4/M5/M6 subtype was better than that of patients with the M4/M5/M6 subtype in the G-CSFepriming
group (67.4%; 95% CI, 53.8% to 80.9% versus 41.9%; 95% CI, 27.1% to 56.6%; P < .05). This study suggests that the
rhG-CSFepriming conditioning regimen is an acceptable choice for HR-AML patients, especially for the patients
with no M4/M5/M6 subtype who achieved CR before transplantation.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.edgments on page 1938.
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High-risk acute myeloid leukemia (HR-AML) has not been
treated with the same success for favorable or intermediate
acute myeloid leukemia [1]. Although the majority of pa-
tients with HR-AML achieve complete remission (CR) after
intensive induction therapy, most of them will die fromood and Marrow Transplantation.
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transplantation (allo-HSCT) is an established treatment for
patients with HR-AML [3], and the ﬁrst choice of a donor for a
patient with allo-HSCT is an HLA-identical sibling. However,
such a donor is not possible for patients with no siblings. The
alternatives are an unrelated HLA-matched donor, umbilical
cord blood, or a family member who serves as an HLA-
haploidentical donor. An unsuccessful or time-consuming
donor search process can limit the application of unrelated
donors for HSCT. Additionally, the outcome of cord blood
transplantation has been limited by incomplete hematopoi-
etic and immune reconstruction [4]. As such, donor avail-
ability is among the major obstacles to the success of
allo-HSCT for the treatment of HR-AML.
The majority of patients have family members who are
identical for 1 HLA haplotype and fully mismatched for the
other, and who can serve as immediate HSCT donors. Thus,
HSCT from an HLA-haploidentical relative offers the option
for treatment with an immediate transplantation for virtu-
ally all HR-AML patients lacking matched donors [5]. Basic
and clinical research on HLA-haploidentical HSCT (haplo-
HSCT) has been ongoing for more than 20 years. The best
survival rate for AML in adults who underwent trans-
plantation after achieving CR is approximately 55%. However,
relapse remains the leading cause of death in patients after
haplo-HSCT, especially those with HR-AML [6]. Accordingly,
the prevention of relapse remains a challenge in the treat-
ment of HR-AML after haplo-HSCT.
Hematopoietic growth factors stimulate AML cells in
culture, activating metabolic processes and the cell cycle.
In vitro, the simultaneous exposure of leukemic cells to
chemotherapy and growth factors, such as granulocyte
colonyestimulating factor (G-CSF), granulocyte macrophage
colonyestimulating factor, and interleukin-3, referred to as
growth-factor priming, increased the susceptibility of cells to
killing by chemotherapy, especially by the cell cycleespeciﬁc
agent cytosine arabinoside (Ara-C) [7-9]. A number of studies
have addressed this concept in the remission induction of
AML patients [10-12]. We previously reported a randomized
trial involving 114 refractory and relapsed AML patients who
were treated with recombinant human G-CSF (rhG-CSF), in
addition to Ara-C, etoposide, and aclarubicin, and we found a
favorable effect of rhG-CSFepriming chemotherapy on the
refractory and relapse AML [13].
Furthermore, rhG-CSF-priming conditioning regimens
have been applied sporadically in the setting of refractory
and relapsed AML patients before allo-HSCT [14]. However,
there have not been any studies on rhG-CSF priming in
myeloablative haplo-HSCT. We conducted a multicenter
randomized controlled study to determine whether treat-
ment with rhG-CSF during the conditioning regimen before
haplo-HSCT improved leukemia-free survival (LFS) in pa-
tients with HR-AML by reducing the rate of relapse.
PATIENTS AND METHODS
Patients and Donors
HR-AML patients (n ¼ 178) who required allo-HSCT but lacked HLA-
matched donors were enrolled in this study. The patients were hospital-
ized at 5 transplantation centers in southwest China. The patients were
included if they fulﬁlled at least 1 of the following criteria deﬁning HR-AML:
no response to induction chemotherapy, relapse within 6 months after in-
duction or consolidation therapy, relapse with 6 months after induction
therapy that could not be relieved using the original induction therapy, 2
relapses or relapse after autologous HSCT, or unfavorable cytogenetics [15].
Patients with serious liver and kidney dysfunction, those who were
considered to have allergic manifestations for rhG-CSF, and those who had
additional tumors in need of treatment were excluded. This study enrolledpatients from October 29, 2007, through June 27, 2011. It was approved by
the ethics committees of the participating institutions and was conducted in
accordance with the Declaration of Helsinki. All of the participants provided
their written informed consent.
Study Design and Conditioning Regimen
The patients were enrolled and randomly assigned to receive the
rhG-CSFepriming regimen or non-rhG-CSFepriming regimen before haplo-
HSCT. The non-rhG-CSFepriming regimen consisted of chlorethyl cyclo-
hexyl nitrosourea, Ara-C, busulfan, cyclophosphamide, and antithymocyte
globulin (ATG). The doses used were as follows: chlorethyl cyclohexyl
nitrosourea 200 mg/m2 orally once on day 9, Ara-C 4 g/m2 once daily
intravenously on days8 to7, busulfan 3.2mg/kg once daily intravenously
on days 6 to 4, cyclophosphamide 1.8 g/m2 once daily intravenously on
days3 to2, and ATG (Thymoglobulin, Genzyme, Cambridge, MA) 2.5 mg/
kg once daily intravenously for 4 consecutive days on days 5 to2. For the
rhG-CSFepriming regimen, rhG-CSF (rhG-CSF, Filgrastim, Kirin, Gunma,
Japan; 5 mg/kg once daily subcutaneously on days 10 to 7) was added to
the above conditioning regimen.
Donor Selection and Stem Cell Graft Harvesting
HLA-A, HLA-B, and HLA-DR typing were performed using a high-
resolution DNA technique [16]. For the 178 haplo-HSCT patients, 114
donors were full haplotypemismatches, 56 donors were haploidentical with
2 mismatched loci, and 8 donors were haploidentical with 1 mismatched
locus. All of the patients received peripheral blood (PB) combined with bone
marrow (BM) HSCT. The donor PB and BM cells were collected using stan-
dard mobilization protocols [16]. Generally, >2.0 $ 108/kg peripheral blood
monocytes,>4.0 108/kg BM nucleated cells, and>6.0106/kg CD34þ cells
were obtained.
Evaluation of Engraftment
Neutrophil engraftment was deﬁned as an absolute neutrophil count
(ANC)  .5  109/L for 3 consecutive days. Platelet engraftment was deﬁned
as a platelet count 20  109/L for 3 consecutive days without transfusion.
Hematopoietic chimerism was evaluated by ﬂuorescence in situ hybridiza-
tion for sex-mismatched patient-donor pairs and by PCR ampliﬁcation of
short tandem repeats using peripheral blood samples from the donor and
the recipient for sex-matched pairs.
Graft-versus-Host Disease Prophylaxis and Management
In addition to basic treatment with ATG in the conditioning regimen, all
of the transplant recipients received cyclosporine (CsA), mycophenolate
mofetil (MMF), and short-term methotrexate (MTX) for graft-versus-host
disease (GVHD) prophylaxis. On day þ1, MTX (15 mg/m2) was adminis-
tered intravenously, and 10 mg/m2 was given on days þ3, þ6, and þ11 after
transplantation. Continuous intravenous CsA (1.5 mg/kg once daily) was
started on day 7, increased to 2.5 mg/kg once daily on day 1, and was
continued until the patients were able to tolerate oral medication. CsA
(2.5 mg/kg twice a day) was given orally with trough levels targeted be-
tween 200 and 400 ng/mL until 180 days; it was then tapered and taken for
an additional 180 days until fully discontinued. MMF (7.5 mg/kg twice per
day) was started on day þ1 and was discontinued on day þ90. Acute GVHD
(aGVHD) and chronic GVHD (cGVHD) were treated as previously described
by Gao L. et al. [16,17].
Infection Prevention and Supportive Care
All patients were cared for in a laminar air ﬂow room and received
prophylactic antibiotics when their ANC was less than .5  109/L. Nor-
ﬂoxacin, trimethoprim sulfamethoxazole, and ganciclovir were routinely
administered as previously reported [18]. All blood products were irradiated
and ﬁltered. Red cell and platelet transfusions were administered to main-
tain hemoglobin levels of >80 g/L and platelet counts >20  109/L. All
patients received rhG-CSF beginning from ANC < .5  109/L after hemato-
poietic stem cell infusion until donor engraftment was achieved.
Statistical Analyses
The date of the last follow-up for all of the surviving patients was June
27, 2013. The primary objective of the study was to determine the effects of
adding rhG-CSF to the conditioning regimen on the cumulative incidence of
relapse and on LFS after haplo-HSCT. A secondary objectivewas to assess the
incidences of engraftment, GVHD, infection and transplantation-related
toxicity (TRT), and overall survival (OS). We had planned to enroll 178 pa-
tients over a close to 4-year period, with an additional follow-up of 2 years
after the enrollment of the last patient. This number of patients would have
given the study a power of 86% to show an absolute increase of 20% in the
rate of 2-year LFS (from 50% to 70%) with the use of rhG-CSF. The Mann-
Table 1
Patient, Donor, and Graft Characteristics
Variable G-CSF Non-rhG-CSF Statistics P Value
No. of patients 89 (100.0) 89 (100.0)
Age at transplantation, yr .139 .889*
<18 22 (24.7) 20 (22.5)
18-40 53 (59.6) 56 (62.9)
>40 14 (15.7) 13 (14.6)
Patient sex .563 .453y
Male 40 (44.9) 45 (50.6)
Female 49 (55.1) 44 (49.4)
Diagnosis of FAB .362 .548y
M4/M5/M6 43 (48.3) 40 (44.9)
No- M4/M5/M6 46 (51.7) 49 (55.1)
Disease status before HSCT .882 .663y
CR1 38 (42.7) 44 (49.5)
CR2 22 (24.7) 19 (21.3)
PR/NR/RE 29 (32.6) 26 (29.2)
HLA compatibility - .795z
1 loci-mismatched 4 (4.5) 3 (3.4)
2 loci-mismatched A, B 28 (31.5) 32 (36.0)
3-loci-mismatched A, DRB1 57 (64.0) 54 (60.6)
Donor-recipient sex match .630 .889y
Female-female 19 (21.4) 18 (20.2)
Female-male 18 (20.2) 21 (23.6)
Male-male 22 (24.7) 24 (27.0)
Male-female 30 (33.7) 26 (29.2)
Donor-recipient relationship .251 .882y
Mother-child 16 (18.0) 15 (16.9)
Father-child 29 (32.6) 33 (37.1)
Siblings 44 (49.3) 41 (46.1)
Prognostic risk category .532 .595*
Favorable 8 (9.0) 8 (9.0)
Intermediate 47 (52.8) 51 (57.3)
Unfavorable 34 (38.2) 30 (33.7)
PR indicates partial remission; NR, nonremission; RE, relapse.
Data presented are n (%).
* Mann-Whitney test.
y Chi-square test.
z Fisher exact test.
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differences in the baseline characteristics, therapeutic effects and adverse
effects between the 2 groups. The Kaplan-Meier analysis and log-rank test
were used to analyze the 2-year LFS and OS of each group. In these analyses,
the patients were recorded as either deceased or censored at the end of the
study.
RESULTS
Patient and Donor Characteristics and Engraftment
Between October 2007 and June 2013, 89 HR-AML pa-
tients were assigned to the conditioning regimen combined
with rhG-CSF (group A) and 89 HR-AML patients were
assigned to the conditioning regimen without rhG-CSF
(group B). The characteristics of the patients and donors
before transplantation are shown in Table 1. The 2 treatment
groups did not differ in their clinical, hematological, cyto-
genetic, or therapeutic features.
All patients received 9.84 (group A: 9.36; group B:
10.03)  108/kg mononuclear cells. The median doses of
infused CD34þ and CD3þ cells were 7.21 (group A: 7.81;
group B: 6.92)  106/kg and 2.14 (group A: 1.88; group B:
2.47)  108/kg, respectively. All patients achieved full donor
chimerism by day 28 after HSCT. ANC exceeded .5  109/L
within 13 days (range, 10 to 18) in group A and 12 days
(range, 10 to 16) in group B. All patients in both groups
achieved platelet engraftment after a median of 16 days
(range, 12 to 23 days in group A; 13 to 26 days in group B).
Secondary granulocytopenia and thrombocytopenia
occurred in 6 patients (2 in group A and 4 in group B). Among
these patients, 3 relapsed on days þ106, þ142, and þ177,respectively, whereas the other patients recovered after
treatment with rhG-CSF and platelet transfusions.
GVHD Incidence and Severity
In group A, 37 (41.6%) patients had grade II aGVHD, and 9
(10.1%) patients had grade III and IV aGVHD. In group B, 34
(38.2%) patients had II aGVHD, and 13 (14.6%) patients had
grade III and IV aGVHD. The 100-day cumulative incidences
of grade II to IV aGVHD and grade III and IV aGVHD were
42.4% (95% conﬁdence interval [CI], 32.0% to 52.9%) versus
39.3% (95% CI, 28.9% to 49.7%) (P > .05) and 10.2 (95% CI, 3.9%
to 16.5%) versus 15.7 (95% CI, 7.8% to 23.6%) (P > .05),
respectively (Table 2, Figure 1). The clinical manifestations of
grade III to IV aGVHD included severe skin rash, diarrhea,
hepatic dysfunction, and hematuria. Methylprednisolone
(2 mg/kg once daily) was administered intravenously and
was tapered as scheduled or based on the therapeutic
response. The 5 patients with grade III aGVHD who were
resistant to methylprednisolone received daclizumab, and
CsA was changed to tacrolimus to control aGVHD. Among
these patients, 3 (1 in group A and 2 in group B) showed
recurrent episodes of serious aGVHD, and they died from
infections on days þ115, þ149, and þ212, respectively.
All patients who survived longer than 100 days after HSCT
were evaluated for incidence of cGVHD. Chronic GVHD
developed in 47 (52.8%) patients in group A and in 35 (39.3%)
patients in group B. In total, 34 of 47 (72.3%) patients in group
A and 25 of 35 (71.4%) patients in group B showed limited
cGVHD when CsA was tapered at the scheduled time (as
Table 2
Clinical Outcomes of rhG-CSF and Non-rhG-CSFePriming Haplo-HSCT
Outcomes rhG-CSF NonerhG-CSF Statistics P Value
Engraftment 89 (100) 89 (100)
Acute GVHD
Grade II 37 (41.6) 34 (38.2) .211 .646*
Grade III-IV 9 (10.1) 13 (14.6) .83 .362*
Chronic GVHD
Total 47 (52.8) 35 (39.3) 3.256 .071*
Limited 34 (38.2) 25 (28.1) 2.054 .152*
Extensive 13 (14.6) 10 (11.2) .449 .503*
Infection within 100 d 4.608 .466*
No infection 10 (11.2) 8 (9.0)
Severe septicemia 16 (18.0) 9 (10.1)
CMV antigenemia 18 (20.2) 24 (27.0)
Zoster 5 (5.6) 3 (3.4)
IFI 7 (7.9) 11 (12.4)
Mixed infection 11 (12.4) 14 (15.7)
Fever 27 (30.3) 23 (25.8)
TRT
Gastrointestinal tract 89 (100) 89 (100) - -
Oral mucositis 60 (67.4) 68 (76.4) 1.780 .182*
Transaminase increase 67 (75.3) 62 (69.7) .704 .401*
Serum creatinine level increase 4 (4.5) 3 (3.4) - 1.000y
Causes of death
aGVHD 2 (2.2) 1 (1.1) - 1.000y
Infection 4 (4.5) 5 (5.6) - 1.000y
Relapse 30 (33.7) 52 (58.4) 10.944 .001*
Two-year OS 59.6 (49.4-69.7) 34.8 (24.9-44.7) 7.825 .005z
Two-year LFS 55.1 (44.7-65.4) 32.6 (22.8-42.3) 8.119 .004z
Data presented are n (%).
* Chi-square test.
y Fisher exact test.
z Kaplan-Meier analysis and log-rank test.
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cGVHD for group A and group B was 53.3 (95% CI, 42.8% to
63.8%) and 39.3 (95% CI, 29.2% to 49.5%), respectively (P >
.05) (Figure 2). Patients with cGVHD remained on CsA/
tacrolimus and steroids (long-term taper).
Leukemia Relapse
Relapse occurred in 34 of 89 (38.2%) patients in group A
and in 54 of 89 (60.7%) patients in group B. The estimated
cumulative incidences of relapse were 38.2% (95% CI, 28.1% to
48.3%) and (60.7% [95% CI, 50.5% to 70.8%], respectively P <
.01) (Figure 3). Next, we performed multivariate analyses
based on the subtype of AML, cytogenetics, and disease
status before HSCT. In group A, the relapse rate of patients
with noM4/M5/M6was lower than that of patients withM4/
M5/M6 (28.3% [95% CI, 15.2% to 41.3%] versus 48.8 [95% CI,Figure 1. The cumulative incidence of aGVHD. (33.9% to 63.8%], P < .05). In group B, there was no difference
between the 2 subtype groups (58% [95% CI, 44.3% to 71.7%]
versus 64.1% [95% CI, 49.0% to 79.2%], P> .05). In both group A
and group B, the relapse rate in patients with CR (CR1
or  CR2) was lower than that of patients with partial
remission, no remission, or relapse. However, there were no
signiﬁcant differences among the different prognostic risk
categories between the 2 groups (Table 3).
The rescue therapy used to treat relapse included donor
lymphocyte infusion in 21 patients, chemotherapy in 19
patients, donor lymphocyte infusion and chemotherapy in 27
patients, haplo-HSCT from the same donors in 4 patients, and
transplants from other haploidentical donors in 7 patients.
Ten patients did not receive any treatment because of rapid,
aggressive relapses. Six patients achieved CR again after the
second transplantation, whereas 78 patients died (52 ofA)Shows Group A and (B) shows group B.
Figure 2. The cumulative incidence of cGVHD. (A) Shows group A and (B) shows group B.
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transplantation-related mortality (TRM) after a second
transplantation).
TRTs and Infectious Complications
All 178 patients had gastrointestinal (GI) toxicity,
including vomiting, anorexia, and diarrhea. 88.8% (158 of
178) patients had grade 1 to 2 GI toxicity, and only 11.2% (20
of 178) patients had grade 3 GI toxicity. Oral mucositis
occurred in 128 patients (60 in group A and 68 in group B, P>
.05), but none suffered from grade 4 oral mucositis. A slightly
elevated transaminase level was commonly observed (67 in
group A and 62 in group B, P > .05). Serum creatinine levels
increased 2-fold or more during the 100 days after trans-
plantation, compared with that before transplantation, in
only 7 patients (4 in group A and 3 in group B, P > .05). No
deaths resulted from lethal organ toxicities from the condi-
tioning regimen during the 100 days after HSCT.
The following infectious complications were observed
during the 100 days after haplo-HSCT: cytomegalovirus
(CMV) antigenemia, 20.2% versus 27.0%; zoster, 5.6% versus
3.4%; severe septicemia, 18.0% versus 10.1%; invasive fungi
infections (IFIs), 7.9% versus 12.4%; mixed infection, 12.4%
versus 15.7%; and fever with no identiﬁable infection, 30.3%
versus 25.8% for group A and group B, respectively. EightFigure 3. The cumulative incidence of relapse in different groups (P ¼ .004)patients with CMV antigenemia developed CMV pneumonia.
These infectious complications, with the exception of 5 cases
of IFIs and 4 cases of severe septicemia, were controllable
with the use of conventional antimicroorganism therapies.
Survival
As of June 30, 2013, 53 patients in group A and 31 patients
in group B were still alive at the median follow-up time of
42 months (range, 24 to 80 months). The causes of TRM
included leukemia relapse in 82 cases, severe infection in 9
cases, and recurrent episodes of serious aGVHD in 3 cases.
The 2-year probabilities of LFS and OS in the group A and
group B were 55.1 (95% CI, 44.7% to 65.4%) versus 32.6 (95%
CI, 22.8% to 2.3%) and 59.6 (95% CI, 49.4% to 69.7%) versus
34.8 (95% CI, 24.9% to 44.7%) (P < .01) (Table 2, Figure 4).
Multivariate analyses indicated that disease status at trans-
plantation and French-American-British (FAB) subtype of
AML were the only signiﬁcant factors (Table 4) (P < .05). In
both groups, the 2-year probability of LFS of patients who
achieved CR before transplantation was better than that of
patients who remained at partial remission, nonremission, or
relapse (63.3% [95% CI, 51.1% to 75.5%] versus 37.9% [95% CI,
20.3% to 55.6%] in group A, P < .05; 38.1% [95% CI, 26.1% to
50.1%] versus 19.2% [95% CI, 4.1% to 34.4%] in group B, P< .01).
The 2-year probability of LFS of patients with no M4/M5/M6
subtype was better than that of patients with the M4/M5/M6
subtype in group A (67.4% [95% CI, 53.8% to 80.9%] versus
41.9% [95% CI, 27.1% to 56.6%], P < .05). In contrast, no dif-
ference was observed in group B (35.9% [95% CI, 20.8% to
51.0%] versus 30.0% [95% CI, 17.3% to 42.7%], P > .05).
DISCUSSION
For decades, the cell cycleedependent agent Ara-C has
been a cornerstone of the treatment of patients with AML.
The combined exposure of AML cells to cytokines, such as G-
CSF, granulocyte macrophage colonyestimulating factor, and
IL-3, with Ara-C increases the intracellular levels of the active
metabolite, cytosine arabinoside triphosphate, elevates the
incorporation of Ara-C into cellular DNA, and enhances the
killing of leukemic blasts and leukemic progenitor cells by
the antimetabolite [19,20]. Previous studies by Pabst [10] and
by our group [13] have shown that AML patients beneﬁted
from rhG-CSFepriming remission conduction, with
improved rates of CR.
In the current multicenter randomized controlled study,
we addressed the effects of different priming conditioning
regimens for HR-AML patients before haplo-HSCT. The
Table 3
Multivariate Analysis of Relapse in rhG-CSF and NonerhG-CSF Priming Haplo-HSCT
Risk Factor rhG-CSF (n ¼ 89) Non-rhG-CSF (n ¼ 89)
Relapse, % (95% CI) Chi-Square P Value Relapse, % (95% CI) Chi-Square P Value
Diagnosis of FAB 4.268 .039 .398 .528
M4/M5/M6 48.8 (33.9-63.8) 64.1 (49.0-79.2)
No- M4/M5/M6 28.3 (15.2-41.3) 58 (44.3-71.7)
Disease status before HSCT 8.402 .004 4.998 .025
CR1 and CR2 28.3 (16.9-39.7) 55.6 (43.3-67.8)
PR/NR/RE 58.6 (40.7-76.5) 73.1 (56.0-90.1)
Prognostic risk category .088 .957 4.058 .131
Favorable 37.5 (4.0-71.0) 37.5 (4.0-71.0)
Intermediate 36.2 (22.4-49.9) 56.9 (43.3-70.5)
Unfavorable 41.2 (24.6-57.7) 73.3 (57.5-89.2)
Kaplan-Meier analysis and log-rank test were used.
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to eradicate micro-residual disease of AML by promoting the
entry of AML cells into the cell cycle with rhG-CSF before the
initiation of high-dose chemotherapy conditioning regimens
for haplo-HSCT. Although all patients in the 2 cohorts
experienced CR after transplantation, the relapse rate of the
patients in group A was lower than that of the patients in
group B. Moreover, the 2-year probabilities of LFS and OS in
group A were higher than those in group B. The signiﬁcant
differences in relapse, LFS, and OS resulted from the activa-
tion of AML cells mediated by rhG-CSF, indicating the po-
tential of the rhG-CSFepriming conditioning regimen
protocol to eradicate leukemia [21,22]. Our data also
compare favorably with recent reports of haplo-HSCT for
hematological malignancies that did not use rhG-CSF before
the conditioning regimen [23,24]. We previously reported
the results of haplo-HSCT using a non-rhG-CSFepriming
conditioning regimen for treating hematological malig-
nancies [16]. This earlier study showed that the probabilities
of 2-year LFS and OS were 68% and 70%, respectively.
Although LFS and OS did not improve in the current study,
the leukemia risk classiﬁcation of the patients enrolled in the
2 studies was different. Speciﬁcally, the current study only
enrolled patients with HR-AML.
After a median follow-up of 42 months, our data showed
that there was no signiﬁcant difference in the incidence of
grade II to IV aGVHD between the 2 groups (42.4% [95% CI,
32.0% to 52.9%] versus 39.3% [95% CI, 28.9% to 49.7%], P> .05).
However, this resultwas lower than the incidences of 55% and
78% that were reported by other investigators in studies inFigure 4. The 2-year probabilities of LFS and OS in different groups. (which G-CSFepriming conditioning regimens were not used
[24,25] and they were similar to our previous results [18].
Similar to that of aGVHD, the incidence of cGVHD was not
signiﬁcantly different between the 2 groups. The lower inci-
dence of aGVHD in our haplo-HSCT recipients in both group A
and group B was associated with GVHD prophylaxis with CsA
plus short-term MTX, MMF, and the addition of ATG to the
conditioning regimen [16]. Many experimental and clinical
studies have reported that the use of rhG-CSF before and/or
after transplantation and the infusion of PB stem cells
mobilized by rhG-CSF, whichmodulates the balance between
Th1 and Th2 cells, could lead to T cell hyper-responsiveness
[26,27]. Morris et al. conﬁrmed that by modifying its
pegylation and using it in combination with Flt-3 ligand,
G-CSF might lead to the activation and ampliﬁcation of
donor-invariant natural killer cells, a marked increase in
post-transplantation cell-mediated CD8þ T cytotoxicity, and
the enhancement of graft-versus-leukemia effects [28]. In the
current study, rhG-CSF was used before and/or after trans-
plantation, and PB stem cells weremobilized by rhG-CSF. The
difference between group A and group B was the application
of rhG-CSF on days 10 to 7. This slight difference in
treatment regimens might have resulted in the small effects
observed on the incidence of GVHD after transplantation.
TRM was also observed in a signiﬁcant proportion of pa-
tients. The leading causes of reported deaths were infections,
GVHD, and TRTs. Perugia et al. [29] reported that 40% of their
patients died of nonrelapse causes and that most of the
deaths were caused by infections, mainly CMV and asper-
gillus. Under the Tuebingen protocol, 7 of 27 adult patientsA) Shows group A (P ¼ .004) and (B) shows group B (P ¼ .005).
Table 4
Multivariate Analysis of Two-Year LFS in rhG-CSF and Non-rhG-CSFePriming Haplo-HSCT
rhG-CSF (n ¼ 89) NonerhG-CSF (n ¼ 89)
LFS, % (95% CI) Chi-Square P Value LFS, % (95% CI) Chi-Square P Value
Diagnosis of FAB 5.927 .015 .259 .611
M4/M5/M6 41.9 (27.1-56.6) 35.9 (20.8-51.0)
No- M4/M5/M6 67.4 (53.8-80.9) 30.0 (17.3-42.7)
Disease status before HSCT 5.624 .018 7.030 .008
CR1 and CR2 63.3 (51.1-75.5) 38.1 (26.1-50.1)
PR/NR/RE 37.9 (20.3-55.6) 19.2 (4.1-34.4)
Prognostic risk category .576 .750 2.230 .328
Favorable 62.5 (29.0-96.0) 50.0 (15.4-84.6)
Intermediate 53.2 (38.9-67.5) 35.3 (22.2-48.4)
Unfavorable 55.9 (39.2-72.6) 23.3 (8.2-38.5)
Kaplan-Meier analysis and log-rank test were used.
L. Gao et al. / Biol Blood Marrow Transplant 20 (2014) 1932e19391938and 2 of 21 children died. Of these patients, 6 had infections
and 3 had GVHD [30]. The Dana Farber group [31] reported
early deaths in 50% of their 24 patients, with the most
common causes being bacterial or fungal. Additionally,
Peking University reported TRMs of 9.1% and 12.7% at day
100 in standard- and high-risk groups, respectively. The
TRMs increased to 19.5% and 31.1% at 2 years, and most of the
TRMs were due to opportunistic infections [24]. In our study,
GI toxicity and oral mucositis were the most common side
effects. Most of the patients had infectious complications
after transplantation, with 6 of 89 patients in group A and 6
of 89 patients in group B dying from IFI, GVHD, or severe
septicemia.
At the same time, we analyzed the inﬂuence of estab-
lished risk factors on outcomes. Interestingly, only the stage
of the disease before transplantation had a signiﬁcant in-
ﬂuence on outcomes, and cytogenetics did not affect the
prognosis of the disease. We also found that not all AML
subtypes beneﬁted from the rhG-CSFepriming conditioning
regimen. The 2-year LFS of FAB-type no-M4/M5/M6 was
better than that of FAB-type M4/M5/M6. This difference
could be explained by the differences in the expression of G-
CSF receptor (G-CSFR) on the different types of blasts. Graf
et al. [32] found that the monocytic subtypes (FAB-type M4/
M5) expressed signiﬁcantly more granulocyte macro-
phageeCSFR, whereas the FAB-type M3 subtype mainly
expressed G-CSFR. Moreover, Kutlay et al. [33] demonstrated
that the G-CSFR expression ratewas higher in theM2 andM3
subtypes and lower in the M5 and M6 subtypes. Recently,
priming with rhGM-CSF during the ﬁrst induction course has
been reported to have positive results, which also supports
our ﬁndings [34].
In summary, the results from this multicenter random-
ized controlled study were encouraging, and they suggest
that haplo-HSCT with rhG-CSFepriming conditioning regi-
mens might be feasible for high-risk AML patients without
HLA-identical siblings or with unrelated donors. According
to the results of multivariate and subtype analyses, the rhG-
CSFepriming conditioning regimen is the best choice for HR-
AML patients with noM4/M5/M6 subtype and who achieved
CR before transplantation.
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